Novo Diabetes Drug Patent Is Obvious, Fed. Circ. Rules
The Federal Circuit on Tuesday affirmed a lower court's ruling that a patent covering Novo Nordisk A/S' diabetes treatment Prandin is invalid as obvious, handing a victory to generics makers Caraco...To view the full article, register now.
Already a subscriber? Click here to view full article